Adeboye Adejare PhD
Adeboye Adejare PhD
Professor of Pharmaceutical Sciences
BS (University of Iowa)
MS (University of Iowa)
PhD, Medicinal Chemistry (Ohio State University)
- Drug targeting
- Mechanisms of neurodegeneration
- Chemistry of fluoroaromatic compounds
- Pharmaceutical profiling
My group is interested in the areas of design and synthesis of small organic molecules to probe neurodegeneration. We are also interested in in vitro models of drug absorption and ability to cross blood brain barrier; drug targeting; pharmaceutical profiling; and chemistry of fluoroaromatic compounds. The major therapeutic areas we focus on are N-methyl-D-aspartate (NMDA) receptor antagonists and gamma-secretase inhibitors. These two mechanisms have been implicated in neurodegeneration as observed in stroke and Alzheimer’s Disease. Our research was/is funded by the National Institutes of Health, the Office of Naval Research, and several pharmaceutical companies. These efforts have resulted in over 30 publications, a patent, and over 80 presentations at meetings, including invited presentations at national and international conferences. Several students from my group have received graduate degrees (MS and Ph.D.) and are employed in academia and the pharmaceutical industry.
Selected Scholarly Activity
S. Sun*, J. Wallach*, and A. Adejare, “Syntheses and N-methyl-D-aspartate Receptor Antagonist Pharmacology of Fluorinated Arylcycloheptylamines”, Medicinal Chemistry, 2014, 10, 843-852.
J. Wallach*, G. De Paoli, A. Adejare, and S.D. Brandt, “ Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl) pyrrolidine (PCPy) analogues, Drug Testing and Analysis, 2013, 6, 633-650, DOI: 10.1002/dta.1468.
N. Coleman, Z. Ates-Alagoz, B. Gaye*, M. Farbaniec, S. Sun* and A. Adejare, "Toxicity Studies on Novel N-Substitued Bicyclo-Heptan-2-Amines at NMDA Receptors", Pharmaceuticals, 2013; 6, 536–545.
Z. Ates-Alagoz, N. Coleman, M. Martin**, A. Wan** and A. Adejare, "Syntheses and In Vitro Anticancer Properties of Novel Radiosensitizers", Chemical Biology and Drug Design, 2012; 80: 853–861.
A. O. Adeniji*, R. M. Wells, and A. Adejare, “Syntheses and In Vitro Evaluation of Novel Adamantane Based g-Secretase Inhibitors”, Current Medicinal Chemistry, 2012, 19, 2458-2471.
Z. Ates-Alagoz. S. Sun*, J. Wallach*, and A. Adejare, “Syntheses and Pharmacological Evaluations of Novel N-Substituted Bicyclo-Heptane-2-amines at N-Methyl-D-Aspartate Receptors”, Chemical Biology and Drug Design, 2011, 78, 25-32.
Member, Editorial Board, Remington: The Science and Practice of Pharmacy; Editor for section on Pharmaceutical Chemistry; 22nd Edition, Pharmaceutical Press, Philadelphia, PA, ©2013.
J. Wallach, B. Gaye, and A. Adejare, “Organic Pharmaceutical Chemistry”, 2013, Remington: The Science and Practice of Pharmacy, 22nd Edition, Pharmaceutical Press, Inc., Philadelphia, PA., 71-101.
Z. Ates-Alagoz and A. Adejare, “Prodrugs”, 2013, Remington: The Science and Practice of Pharmacy, 22nd Edition, Pharmaceutical Press, Inc., Philadelphia, PA., 175 – 194.
Boyenoh Gaye*, Zeynep Ates-Alagoz, and Adeboye Adejare; Bicyclo-heptan-2-amines; USA # 8,735,590 B2, May 27, 2014.
Adeboye Adejare; Non-Competitive NMDA Receptor Antagonists, USA # 8,703,799 B2; April 22, 2014.
Novel Compounds for Treatment of Malignant Tumors, Constantinos Koumenis, Brian E. Lilly, Steven Kridel, Gary Kao, and A. Adejare, USA # 8,541,476 B2, September 24, 2013.
A. Adejare, Non-Competitive NMDA Receptor Antagonists, USA # 8,129,414, 2012.
** Undergraduate Student
* Graduate Student
|Office location:||PharmTox 242|
|Mailing address:||Box 80|
a [dot] adejar [at] usciences [dot] edu